Enliven Therapeutics, Inc.
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
ELVN | NDAQ
Overview
Corporate Details
- ISIN(s):
- US29337E1029 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 6200 LOOKOUT ROAD, 80301 BOULDER
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology. The company engages in the discovery and development of small molecule kinase inhibitors to treat various forms of cancer. Its approach is centered on creating therapies with enhanced efficacy through improved selectivity and combinability, with a goal to combat drug resistance, address brain metastases, and improve patient safety and convenience. By leveraging an experienced team of drug development experts, Enliven aims to help cancer patients live longer and better lives through its pipeline of innovative therapeutics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Enliven Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Enliven Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Enliven Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
